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Review
Biomedical Applications of DNA-Based Hydrogels
Jasmina Gacˇanin, Christopher V. Synatschke,* and Tanja Weil*
Nucleic acids are gaining significant attention as versatile building blocks 
for the next generation of soft materials. Due to significant advances in the 
chemical synthesis and biotechnological production, DNA becomes more 
widely available enabling its usage as bulk material in various applications. This 
has prompted researchers to actively explore the unique features offered by 
DNA-containing materials like hydrogels. In this review article, recent devel-
opments in the field of hydrogels that feature DNA as a component either in 
the construction of the material or as functional unit within the construct and 
their biomedical applications are discussed in detail. First, different synthetic 
approaches for obtaining DNA hydrogels are summarized, which allows clas-
sification of DNA materials according to their structure. Then, new concepts, 
properties, and applications are highlighted such as DNA-based biosensor 
devices, drug delivery platforms, and cell scaffolds. With the 2018 Nobel Prize 
in Physiology or Medicine being awarded to cancer immunotherapy under-
scoring the importance of this therapy, DNA hydrogel systems designed to 
modulate the immune system are introduced. This review aims to give the 
reader a timely overview of the most important and recent developments in this 
emerging class of therapeutically useful materials of DNA-based hydrogels.
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1. Introduction
The great progress in DNA synthesis and the consequent 
accessibility of larger DNA quantities has prompted a material 
revolution by implementing DNA as a functional entity in the 
design of biohybrid materials.[1] Modern DNA synthesis tech-
niques enable rapid preparation or amplification of effectively 
any DNA sequence in large quantities by automated techniques, 
polymerase chain reaction (PCR), or production in microorgan-
isms.[2,3] In comparison to other biopolymers, such as proteins 
or polysaccharides, DNA consists only of a small set of nucleic 
acid monomers. However, their highly 
specific and predictive interaction between 
the monomer units with the respective 
complementary nucleic acids (AT and GC) 
facilitates spontaneous and convenient 
programming of synthetic 2D and 3D 
structures in solution.[4] Even small DNA 
building blocks like DNA bricks can be 
combined to produce predictable assem-
blies of thousands of individual compo-
nents.[5] Furthermore, DNA has great 
mechanical rigidity, thus it can serve as a 
rigid rod spacer for the precise positioning 
of tethered nanoparticles or functional 
molecular components along the polymer 
chain.[6,7] Recently, the development of 
more complex DNA scaffolds allowed the 
spatial arrangement of functional pro-
teins within multifunctional assemblies.[8] 
Moreover, DNA-based materials can 
exhibit dynamic and adaptable properties 
due to the supramolecular nature of the 
interaction of complementary nucleic acid 
sequences. These materials can, e.g., pre-
sent bioactive molecules in a dynamic and reversible fashion, 
which allows controlling their cellular interactions.[9]
Moreover, the high physicochemical stability of DNA nano-
structures[10] can be modulated by external triggers. While DNA 
double strands show a distinct thermally triggered dissociation 
behavior (melting temperature), an increase in thermal stability 
of DNA double helices can be achieved through intercalating 
agents, like psoralen, or via photo-cross-linking.[11–13] Finally, 
a large number of tools are provided by nature in the form of 
highly specific enzymes, such as endonucleases,[14–16] exonu-
cleases,[16,17] polymerases,[16–19] and ligases[16,17] that allow the 
DNA material to be processed or degraded efficiently and with 
a high level of precision.
Based on these features, DNA has stimulated new directions 
in materials design (Figure 1). For instance, its precise hybridi-
zation into 2D and 3D objects has culminated in the develop-
ment of several bottom-up fabrication processes such as DNA 
origami, where a circular, single-stranded DNA template is 
predictably folded into precise nanostructures with short DNA 
sequences, called staple strands.[20] Furthermore, as DNA objects 
are now becoming more readily available, they become increas-
ingly useful, e.g., as precision templates for the construction of 
precise 2D and 3D polymeric architectures.[21–23] Since DNA is a 
strongly hydrophilic polyelectrolyte, it can absorb large amounts 
of water, sparking an interest in DNA for hydrogel design.[24,25] 
In this respect, DNA is an excellent component for the con-
struction of supramolecular hydrogels, as it imparts important 
features such as biocompatibility, controlled biodegradability, 
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permeability for nutrients, adjustable mechanical proper-
ties, stability against proteases, the ability for self-healing, and 
responsiveness to various stimuli to the hydrogel.[26,27] In com-
parison to DNA, many other noncovalently cross-linked hydro-
gels derived from natural sources like alginate or gelatin, lack 
this level of versatility and structural programmability.[26] There-
fore, smart DNA hydrogels combine many desirable features 
for preparing customized materials for biomedical applications 
that cannot easily be achieved with other materials.
In this review, we summarize the underlying design principles 
for the construction of DNA-based hydrogels and highlight their 
applications in different fields of biomedicine (Figure 2). In con-
trast to other recent reviews on DNA hydrogels,[28–32] we particu-
larly focus on their applications in emerging fields such as bio-
sensing, drug delivery, immunotherapy, and tissue engineering 
and we discuss their unique features as well as current limitations.
2. Design of Nucleic Acid-Based Hydrogels
DNA-based hydrogels have been prepared based on different 
design principles.[28–31,33] The selected design and preparation 
methods have a strong impact on the characteristic features of 
DNA hydrogels and thus determine their respective biomedical 
applications. In this section, we introduce 1) hydrogels that con-
sist entirely of DNA, and 2) the usage of DNA as versatile and 
biocompatible cross-linkers in combination with synthetic poly-
mers as well as 3) materials containing short DNA sequences 
as functional grafts providing access to customizable hydrogels 
with unique bio-specificity.
2.1. “All-DNA” Hydrogels based on Polynucleotide Scaffolds
Today, based on the seminal work of Luo and colleagues, who 
achieved the first self-supporting all-DNA hydrogel, DNA can 
be considered as a building unit for bulk macroscale materials. 
This hydrogel reported by Um et al. in 2006 was prepared 
from branched and flexible 3D DNA, which was designed to 
associate with other complementary strands under network 
formation.[34] Several strategies to produce hydrogels made 
entirely from DNA sequences followed and have since been 
reported.[13,35–37] In the first approach, preformed DNA building 
blocks are mixed in solution, which then form a 3D network 
due to the interactions of complementary DNA strands on 
separate building blocks (Figure 3a). Binding between the 
building blocks can be achieved through hybridization of DNA 
sticky ends,[35] i-motifs,[36] or enzymatic ligation[34] as depicted 
in Figure 3a,b. The i-motif represents a tetrameric structure 
of cytosine-rich DNA sequences that self-assemble into a four-
stranded complex.[36,38] These assemblies are formed at pH 5 
and dissociate at pH 8, thus introducing a rapid, pH-responsive 
sol–gel transition of i-motif-containing materials.
All-DNA gels were also generated in more recent work by 
in situ formation of the building blocks, e.g., by enzymatic 
polymerase amplification reactions. Using branched, Y-shaped 
primers that are thermally stabilized by psoralen treatment, 
hydrogels can be prepared by PCR via extending and connecting 
the forward and reverse primers.[13] An intriguing example of 
gel formation by DNA polymerization uses combined rolling 
circle amplification and multi-primed chain amplification to 
build extremely long DNA sequences that eventually form gels 
through entanglement rather than predetermined cross-linking 
points (Figure 3c).[37]
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The selected cross-linkers in all-DNA hydrogels strongly 
influence the material properties of the resulting gels. Hydro-
gels made by hybridization of sequences with complementary 
sticky ends can undergo sol–gel transitions upon heating,[35] 
or by pH-changes[36] and they can be reversibly cycled through 
liquid–solid phase transitions. In contrast, gels made by enzy-
matic ligation are covalently cross-linked networks that do 
not undergo reversible sol–gel transitions.[34] In addition, the 
application of enzymatic DNA polymerization techniques can 
result in gels with metamaterial properties exhibiting solid-
like behavior when immersed in water and liquid-like behavior 
after water removal.[37] Furthermore, after complete deforma-
tion due to removal of water, the material shows shape-memory 
behavior as it recovers its original shape upon addition of 
water.[37] Similarly, Chen and Romesberg used PCR amplifica-
tion in combination with two specially synthesized forward and 
reverse bottlebrush primers to form DNA hydrogels that exhibit 
hierarchical architectures.[39] These gels have been rendered 
catalytically active by incorporating streptavidin-modified horse-
radish peroxidase after amplification of biotinylated bottlebrush 
primers, which could be attractive for encapsulation of specific 
guest molecules without loss of protein function.[39]
Although all-DNA-based hydrogels reveal many unique prop-
erties, there are still several limitations that need to be overcome 
to facilitate their usage in biomedicine. First of all, very few 
functional groups are available in DNA, which makes further 
chemical modifications rather challenging and limits customi-
zation of the functional properties of the hydrogel. In addition, 
some intrinsic limitations of DNA, such as its highly negative 
net charge, limited stability, and high synthesis costs currently 
prevent upscaling that would be necessary for in vivo biomedical 
applications. Consequently, only very few examples have been 
reported, in which all-DNA hydrogels have been used beyond 
proof-of-concept demonstrations, e.g., in 3D printing.[40,41]
2.2. Oligonucleotides as Cross-linkers
Some of these limitations may be overcome by combining 
hydrophilic polymer scaffolds with short DNA sequences acting 
as supramolecular cross-linking agents.[26,29,42] Such hydrogels 
utilize both the smart and programmable features of the DNA 
components as well as the chemical flexibility, stability, and acces-
sibility of hydrophilic polymers to optimize functional perfor-
mance. In this way, bulk materials are more readily available and 
several of the unique material characteristics of DNA are retained.
In 1996, Nagahara and Matsuda reported the first DNA-
containing polymer hydrogels that were based on short DNA 
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Figure 1. Timeline of notable discoveries and developments in DNA technology and their relevance for DNA-containing hydrogels.
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sequences grafted to a poly(acrylamide) polymer chain.[43] The 
authors demonstrated two pathways of achieving gelation: In 
so-called Type I hydrogels, a soluble DNA sequence hybrid-
ized with two other DNA strands attached to a polymer back-
bone, thereby inducing gelation (Figure 4).[43] In contrast, Type 
II hydrogels had complementary DNA strands attached to the 
polymer chain and gelation occurred in situ without the addi-
tion of external gelators (Figure 4).[43]
Following this seminal work, various DNA-polymer hybrid 
materials have been prepared with customized sol–gel transi-
tions that are externally controlled by complementary DNA 
strands.[44–46] Complex DNA cross-linking elements such as 
Y-shaped DNA,[47–49] i-motifs,[50] or DNA mismatch elements[51] 
have also been introduced into polymeric hydrogels (Figure 4, 
Table 1). Y-shaped DNA provides hybridization, gelation, and 
functionalization of hydrogels in one step, where the DNA link-
ages could be severed by heat, enzymes, or mechanical stress 
thus yielding gels with attractive multi-responsiveness and thixo-
tropic behavior.[47–49] Light-responsiveness has been achieved by 
incorporating an azobenzene-modified ssDNA into an acrylamide 
hydrogel inducing macroscopic volume changes of the dynamic 
hydrogel upon alternating irradiation with visible and UV light.[52] 
Furthermore, by exploiting the possibility to mismatch the sticky-
end sequences, hydrogels with tunable mechanical and thermal 
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Figure 2. Overview of the manifold applications of DNA-based hydrogels in the biomedical field. Highlighted examples include biosensing, drug 
delivery, immuno-modulation, and cell-based approaches. Printable sensors: Adapted with permission.[41] Copyright 2018, Wiley-VCH. Target sensing: 
Adapted with permission.[107] Copyright 2017, Royal Society of Chemistry. Cell regulation: Adapted with permission.[49] Copyright 2017, Wiley-VCH. 
Controlled release (top): Adapted with permission.[143] Copyright 2018. American Chemical Society. Controlled release (bottom): Adapted with permis-
sion.[73] Copyright 2012, American Chemical Society. Vaccination: Adapted with permission.[149] Copyright 2015, Elsevier. Immunotherapy: Adapted with 
permission.[162] Copyright 2018, American Chemical Society. Morphology switch: Adapted with permission.[180] Copyright 2018, American Association 
for the Advancement of Science. Designer ECM: Adapted with permission.[183] Copyright 2016, Wiley-VCH. Catch and release: Adapted under the terms 
of the Creative Commons Attribution 4.0 International License.[76] Copyright 2015, The Authors.
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properties were obtained.[51] Mismatches refer to regions within 
the sticky-ends of the DNA cross-linker that are partially comple-
mentary to the ssDNA grafted on the polymer backbone.[51]
Moreover, (multi)-stimuli-responsive gels,[42,50,53–63] 
logic gates,[64] and shape-memory[42,56,62,63] hydrogels have 
been reported based on DNA cross-linkers by additionally 
implementing DNA motifs like i-motifs, guanine quadruplex 
units, or aptamers (Figure 4c and Table 1). Briefly, guanine quad-
ruplexes are formed from guanine-rich nucleic acid sequences, 
where four guanine bases associate through hydrogen bonding 
to adopt a square planar structure, which is stabilized by ions like 
K+. Aptamers (Latin from aptus—fit, Greek from meros—part) are 
single-stranded DNA or RNA sequences that can selectively bind 
various substrates such as small molecules,[65–67] proteins,[68–74] 
or even cells,[75–77] with affinities comparable to antibodies.
The switching of multi-responsive hydrogels can be achieved 
by several cooperative stimuli-responsive DNA cross-linking 
motifs, each dictating the hydrogel properties. In this way, 
controlled dissociation and reassembly occurs, transitioning 
the hydrogel between different states such as stiff or quasi-
liquid states.[42] These gels can even function as logic gates, 
i.e., dissociation only occurs in the presence of two distinct 
target molecules but they remain intact if only one or none of 
the target molecule is present.[64] In shape-memory hydrogels, 
e.g., via the i-motif bridging units, cooperative cross-linking 
of nucleic acid-functionalized polymer chains has been 
reported.[62] Thereby, the two cooperative cross-linking strate-
gies retain a certain hydrogel shape. Upon dissociation of one 
cross-linker, a “memory code” in the quasi-liquid state is pro-
vided by the other, still intact cross-linking unit allowing reor-
ganization into the original shape.[42,62]
2.3. Oligonucleotides as Bioactive Groups  
or as Tags for Functionalization
Hydrogels incorporating DNA segments as functional, bioac-
tive elements and not as structural components have also been 
explored for various biomedical applications.[49,68,70–77] The 
presence of DNA as a bioactive group in these hydrogels typi-
cally does not significantly alter the mechanical properties of 
the gel, but rather imparts important interactions with thera-
peutically relevant molecules[49,68,70–74] or cells.[75–77]
Functionalization of DNA hydrogels is straightforward, 
only requiring introduction of short DNA sequences com-
prising the desired functionality during[47–49] or after gela-
tion.[78] These DNA tags hybridize complementary DNA 
strands at the polymer backbone or within the already formed 
hydrogel (Figure 4d). Similarly, phosphoramidite derivatives 
provide a synthetic route of oligonucleotides that are func-
tionalized with a methacryl group at the 5' end DNA (also 
called acrydite-modified DNA) and can subsequently be 
added during the gel-forming polymerization reaction of, i.e., 
acrylamide.[79–82]
Previously, DNA strands have been modified with reactive 
groups such as amine, carboxyl, thiol, or alkyne groups, as well 
as azobenzenes as light-sensitive switches, bioactive peptides, 
or proteins.[83,84] Moreover, therapeutically active compounds[49] 
or biomimetic signals[9] have been attached to the hydrogels, 
making them responsive toward enzymes or enabling strand 
displacement for controlled release of functional molecules. 
A potential drawback of the post-functionalization method of 
already formed gels is the need to infiltrate the hydrogel with 
the functionalized DNA tags, which could be sterically or elec-
trostatically hindered, particularly if larger DNA structures 
need to be incorporated.
In addition to the already mentioned reactive functionali-
ties and bioactive entities, aptamers have gained significant 
interest because of their high specificity toward a wide range 
of biological target molecules and the opportunity to selectively 
introduce functional molecules to the hydrogel (Figure 4e). 
Compared to antibodies, aptamers can have significantly 
smaller molecular weights, and they can be easily tailored 
for different targets, which makes them attractive as com-
ponents in bioassays[85,86] or as therapeutics for treatment of 
diseases such as eye disorders, thrombosis, vascular diseases, 
and cancer.[68] Aptamer sequences with high target-specific 
binding affinity values are generated by an in vitro selection 
process called systematic evolution of ligands by exponential 
enrichment.[87,88] One drawback of the application of aptamers 
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Figure 3. All-DNA hydrogels formed by a) hybridization of Y-shaped 
DNA[35] and i-motifs,[36] b) enzyme-catalyzed assembly,[34] and c) entan-
glement of long DNA chains formed via DNA polymerase chain ampli-
fication.[37] a) Adapted with permission.[35,36] Copyright 2009 and 2010, 
Wiley-VCH. b,c) Adapted with permission.[34,37] Copyright 2006 and 2012, 
Springer Nature.
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is their low cellular uptake due to their high negative charge 
density[89] as well as their limited stability in the presence of 
DNA degrading enzymes that are typically present in cells.[90] 
However, there are promising strategies to optimize their 
function, reduce their susceptibility to nuclease degradation, 
and improve the stability of aptamers to broaden their scope 
for biomedical applications.[68,90,91]
In the following, DNA hydrogels that were prepared by 
the already discussed design strategies and based on the 
introduced structural components are reviewed in view of 
their biomedical applications. We mainly focus on applica-
tions of DNA hydrogels as matrices for biosensing, as vehi-
cles for drug delivery and immunomodulation, as well as 
their applications for cell-based approaches such as tissue 
engineering.
2.4. Critical Comparison with Non-DNA Cross-linkers  
in Supramolecular Hydrogels
While DNA-containing hydrogels are an emerging material 
for biomedical applications, competing systems consisting 
of, e.g., biopolymers and peptides can also offer certain 
advantages. In the following, we critically compare a limited 
number of hydrogel systems that share certain aspects of the 
DNA-containing hydrogels discussed in this review. Similar 
to DNA, peptide sequences can also participate in (self-)rec-
ognition events, that lead to, i.e., the formation of α-helical 
or β-sheet structures. These features have been used to gen-
erate noncovalently cross-linked hydrogels by using short 
β-sheet-forming peptide-grafts as cross-linking sites to afford 
hybrid hydrogels with inner fibrillary structures.[92–94] Other 
Adv. Funct. Mater. 2019, 1906253
Figure 4. Oligonucleotides as hydrogel cross-linkers by a) direct DNA hybridization,[43] b) ssDNA linker units[43,48] including DNA origami linkers, or 
c) structure elements like i-motifs[50] or guanine quadruplex units.[41] Functional hydrogels by d) hybridization of modified DNA sequences[48] or by 
e) implementing aptamer sequences into the hydrogel.[57] Aptamers can bind various biological target structures. a) Adapted with permission.[43]  
Copyright 1996, Elsevier. b) Left: adapted with permission.[43] Copyright 1996, Elsevier. Right: adapted with permission.[48] Copyright 2014, Royal 
Society of Chemistry. c) Left: Adapted with permission.[50] Copyright 2014, Wiley-VCH. Right: Adapted with permission.[41] Copyright 2018, Wiley-VCH. 
d) Adapted with permission.[48] Copyright 2014, Royal Society of Chemistry. e) Adapted with permission.[57] Copyright 2008, American Chemical Society.
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examples include the coiled-coil motif and collagen mim-
icking peptides which, based on the simplicity and regularity, 
have been extensively studied in this context as well.[95–100] 
The structure formation of coiled-coil and collagen mim-
icking peptides is affected by the number of repeat units, 
pH, ionic strength, temperature, and concentration. Con-
sequently, a variation of the peptide or graft copolymer 
concentrations affect certain hydrogel characteristics (e.g., 
gelation time, morphology, stiffness, melting point tem-
perature) and can be used to introduce stimulus responsive 
behavior.[98,101,102] Recently, these systems have been exten-
sively reviewed and there has been much progress to design 
such hydrogels for biomedical applications.[101,103] One of the 
major advantages of these peptide-containing hydrogels is 
their promising scalability compared to the significant costs 
still associated with DNA synthesis. In terms of mechanical 
properties, DNA-containing hydrogels often do not out-
perform alternative systems without DNA. However, DNA 
reveals exceptional recognition properties, which drastically 
increases the programmability of DNA-containing materials 
and enhances their functional applications in particular for 
biosensing, drug delivery, and tissue engineering as dis-
cussed in the next sections.
3. Biomedical Applications of Nucleic Acid-Based 
Hydrogels
3.1. DNA-Based Hydrogels for Biosensing
The qualitative and quantitative detection of various analytes 
in vitro and in vivo is vital in many biomedical fields spanning 
clinical diagnosis and point-of-care testing to detecting trace 
targets in personalized healthcare, environmental monitoring, 
and food safety.[104,105] Particularly, portable and visual detection 
methods provide the technology for devices that are fast, simple 
to operate, and do not require special instruments.[104,105] In 
this context, target-specific stimuli-responsive DNA hydrogels 
could serve as a portable, sensitive, selective, and low-cost bio-
sensor platform.
Adv. Funct. Mater. 2019, 1906253
Table 1. DNA-motifs used for cross-linking of DNA hybrid hydrogels. While reversible transitions between DNA-based polymer hydrogels and DNA-
polymer solutions or quasi-liquid states can be implemented by employing different triggers like strand displacement, target-responsiveness, pH, 
and different ions for G-quadruplexes, or metal ions, they also offer the potential to construct smart shape-memory hydrogels when combining 
orthogonal stimuli.
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Typical design strategies of biosensor hydrogels employ a 
synthetic polymer as the scaffold and an analyte-binding, func-
tional DNA cross-linker as the sensor. The cross-linker dissoci-
ates only after recognition of the respective target compound 
and reports its presence by inducing changes in hydrogel 
swelling volume, mass, mechanical properties, or by the release 
of an encapsulated cargo generating a readout signal.[106,107] 
To date, different target-responsive DNA hydrogels have been 
reported[104–106] for the detection of ions,[81,108,109] small mole-
cules,[53,57,64] proteins,[110] viruses,[111] or toxins.[112,113] In certain 
cases, the readout from these DNA-based devices is even visible 
to the unaided eye, without the need for sophisticated equip-
ment and is also preserved in biological matrices including 
urine, serum, and lacrimal fluid.[53,110,111,114,115] This feature has 
been exploited for specific recognition of thrombin, which is 
relevant in the context of glomerulonephritis, an inflammation 
of the kidney's filtering systems which occurs in certain can-
cers, diabetes, hepatitis, or the autoimmune disease Systemic 
Lupus Erythematosus.[110,111,116] As the signal readout is one of 
the central differentiating elements of biosensors, the detection 
of various biomedical targets and metabolites by colorimetric, 
volumetric, or conformational interconversion as well as the 
development of electrochemical readout strategies for printable 
sensors are highlighted in the following sections.
Recently, Mao et al. described the sensitive and visual 
detection of different targets employing a functional DNA 
cross-linked hydrogel (Figure 5a).[107] The hydrogel was based 
on aptamers or DNAzymes, DNA oligonucleotides catalyzing 
certain chemical reactions, as a target-responsive unit that 
was incorporated into hydrogels able to bind ions or small 
molecules. In addition, glucoamylase, an enzyme that cata-
lyzes the digestion of amylose to glucose, was encapsulated 
for both molecular recognition and signal amplification.[107] In 
these gels, gold nanorods served as a multicolor readout cir-
cuit for monitoring the target concentration, e.g., Pb2+, with 
high sensitivity. Lead concentrations of about 50–100 × 10−9 m  
were detected with this system by simple visual inspection. 
Thus, portable hydrogels with DNAzyme–substrate complexes 
as cross-linkers of a DNA-grafted polyacrylamide polymer back-
bone even allowed visual quantification of lead ion concentra-
tions in aqueous solutions.[107] Important biomarkers such as 
adenosine,[57,105,117] which acts as a signaling molecule in the 
peripheral and central nervous system and also represents a 
cancer biomarker for monitoring disease progression,[105] as 
well as thrombin[57] have been detected by similar colorimetric 
assays. Colorimetry is the detection method of choice in most 
DNA hydrogel biosensors as it allows the straightforward detec-
tion of target analytes such as metal ions[108,117] and small mole-
cules,[105,115,117,118] e.g., for environmental monitoring, forensic 
analysis, detection of drug misuse, and medical diagnosis. 
However, this technique often provides only semiquantitative 
analysis and relatively low sensitivity.[119]
To overcome these limitations, Liu et al. used a molecular 
imprinting approach to form hydrogels that undergo mac-
roscopic volumetric shrinkage in the presence of target pro-
teins.[110] Such hydrogels were formed by aptamers carrying 
a polymerizable methacrylamide group together with bifunc-
tional aptamer–protein complexes as small cross-linkers. In this 
way, the proteins thrombin and PDGF-ββ, which are released 
during blood clotting and serve as biomarker for angiogenesis 
and atherosclerosis, were imprinted into the gel. The resulting 
gels showed remarkable sensitivity down to femtomolar con-
centrations of PDGF-ββ. In addition, the dried gels were 
stable for extended time periods and could be re-hydrated on 
demand.[110]
The development of surface-immobilized DNA hydrogels 
as printable sensors and for bioelectronics has been explored 
recently where applications in the fields of personalized medi-
cine and clinical diagnosis are anticipated.[41,119,120] Mao et al. 
reported the first surface-immobilized pure DNA hydrogel bio-
sensor (Figure 5b).[120] The soft DNA hydrogel scaffold was syn-
thesized via a surficial primer-induced strategy on a transparent 
electrode, allowing both colorimetric and electrochemical detec-
tion. The resulting immobilized 3D DNA hydrogel scaffold 
was employed to capture enzymes, providing a stable catalytic 
system for biosensing. On account of the molecular sieving 
effect and the good swelling/de-swelling properties, direct sen-
sitive detection of targets such as bilirubin in serum samples 
was successfully demonstrated. Furthermore, fast regeneration 
of the material and preservation of the catalytic activity after a 
few cycles was achieved.[120] The observed low detection limit of 
bilirubin of 32 × 10−9 m was proposed to allow for applications 
in the diagnosis of jaundice.[120]
Zhong et al. reported on a DNA hydrogel-based, highly selec-
tive and sensitive sensor for Pb2+ detection (Figure 5c), which 
was based on conformational interconversion that induces 
changes in the catalytic activity with impressive responses 
between 1 × 10−12 and 50 × 10−9 m. The hydrogel was con-
structed from a guanosine-borate monoester with subsequent 
K+-templated assembly into guanine quadruplexes (G4-DNA, 
as discussed in Section 2.2, Figure 4c). Guanine quadruplexes 
incorporate hemin and display enzyme-like activity.[40] The 
sensing event is based on Pb2+ substituting K+ within the com-
plex and subsequently inducing a conformational interconver-
sion to more compact structures that trigger hemin release.[40] 
This subsequent loss in catalytic activity was detected as 
changes in the absorbance that contribute to the high sensitivity 
of the sensor.[40] The authors suggest that the system provides 
a novel platform for sensing, biomolecular computation, and 
drug delivery, due to its facile construction combined with long-
term stability (up to 28 days), high sensitivity, and selectivity.[40]
The immense potential of this setup for flexible next-gen-
eration sensors and bioelectronics was also underlined by the 
in situ fabrication of a semiconducting hydrogel as a glucose 
biosensor (Figure 5d).[41] This biosensor was fabricated by 
loading the enzyme glucose oxidase into the DNA hydrogel as a 
catalytic matrix for the oxidation of aniline and the in situ dep-
osition of polyaniline. In this way, the biosensor was directly 
printed into a flexible electrochemical electrode. This detection 
system revealed excellent electrochemical properties, long-
term and cycle stability and was compatible with 3D printing, 
rendering it a promising material for flexible electrochemical 
applications such as the development of self-regulated insulin 
delivery devices.[41]
Another DNA hydrogel-based electrochemical biosensor was 
designed for the detection of microRNA that is specific to lung 
cancer.[119] The hybrid hydrogel was immobilized on an indium 
tin oxide/polyethylene terephthalate (ITO/PET) electrode, and 
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Figure 5. DNA-based hydrogels for biosensing. a) Target-responsive readout-unit release via gel–sol transition for colorimetric readout. The target-
responsive strand can be an aptamer resulting in strand displacement and hydrogel collapse. Alternatively, a DNAzyme is activated by the target to cut 
the cross-linking strand. Enzymes like glucose amylase can be used as readout-unit catalyzing colorimetric reactions for visual detection. AuNRs served 
as a multicolor substrate. Adapted with permission.[107] Copyright 2017, Royal Society of Chemistry. b) Printable surface-immobilized DNA hydrogels 
with high spatial definition. Surface-immobilized 3D DNA hydrogels were constructed on a transparent ITO electrode using a surficial primer-induced 
strategy for both colorimetric and electrochemical readout. For biosensing, the hydrogel can wrap enzymes for detection of, e.g., bilirubin in serum.[120] 
Adapted with permission under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license.[120] Copyright 2018, The Authors. 
Published by Royal Society of Chemistry. c) Target-responsive DNA hydrogel based on catalytic interconversion resulting from conformational transi-
tion via cation substitution. The hydrogel comprised a G4-quartet motif with hemin and complexed K+ ions forming a catalytically active material. 
Cation substitution with Pb2+ forms more compact structures and simultaneous loss of hemin is followed by drastic change in the catalytic activity 
of the hydrogel where the H2O2/3,5,3,5-tetramethylbenzidin (TMB) oxidation was chosen as a model reaction. Adapted with permission.[40] Copyright 
2018, American Chemical Society. d) Flexible electrochemical biosensors. Enzyme-mimicking hydrogel matrix catalyzes the in situ oxidation of aniline 
yielding the deposition of polyaniline on G-quartet nanofibers. Detection of glucose was demonstrated by loading glucose oxidase enzyme (GOx) into 
the hydrogel. Adapted with permission.[41] Copyright 2018, Wiley-VCH.
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DNA-grafted polyacrylamide cross-linked by ferrocene-tagged 
DNA served as a recognition probe.[119] Upon hybridization of 
the recognition probes with the target miRNA, the hydrogel 
dissociated, resulting in a loss of ferrocene tags and, hence, a 
reduction in measurable current.[119] This biosensor was able to 
detect concentrations as low as 5 × 10−9 m (1 pmol) and showed 
a linear readout ranging between 10 × 10−9 and 50 × 10−6 m. It 
was highly sensitive, and showed good stability and selectivity. 
Furthermore, it can be applied toward a diversity of other tar-
gets as the recognition probe has a flexible sequence design.[119] 
These strategies indicate that DNA hydrogels could be inte-
grated into surface biosensing devices, thereby, broadening 
hydrogel applications in the field of diagnosis, personalized 
medicine, and environmental monitoring. Future challenges 
lie in the development of sensing devices that have improved 
stability and are operational under a wide range of environ-
mental conditions. In particular, the ability to accurately detect 
and quantify trace amounts of analytes in complex body fluids 
still represents a great challenge. In addition, current DNA 
hydrogel-based sensors are quite costly preventing their appli-
cation as single-use devices. Therefore, either the reusability of 
these sensors needs to be significantly improved, or the pro-
duction costs have to be substantially lowered. With the advent 
of personalized medicine, the need for individualized bioana-
lytics is gaining much attention. We anticipate that if the above-
mentioned challenges can be addressed, DNA hydrogel sensors 
will offer great potential in future personalized medicine as 
implantable sensors or for in vivo diagnostics.
3.2. DNA-Based Hydrogels for Drug Delivery Applications
One major concern in drug delivery is the capability to store and 
release drug molecules or therapeutic proteins in a controlled 
spatio-temporal fashion, i.e., based on changes in pH, tempera-
ture, the presence of enzymes, or light.[121] In this section, we 
discuss the customization of DNA hydrogels for various drug 
delivery applications to address tumor tissue or bone cells locally. 
First, examples dealing with hydrogels capable of releasing 
small molecules or therapeutic proteins are summarized. 
Then, more sophisticated drug depots that can target specific 
cells and release their cargo in response to changes in their 
environment or due to other external triggers are discussed. 
Finally, we present selected examples of such gels capable of 
storing and delivering therapeutic proteins in a spatio-temporal 
fashion in the context of different diseases such as osteoporosis.
Early hydrogel formulations based on enzymatically 
cross-linked DNA hydrogels lacked a specific ability to retain 
target molecules within the network, and their release kinetics 
were determined predominantly by diffusion parameters.[34] In 
recent years, DNA hydrogels have become more advanced and 
can now release drugs in a controlled fashion to improve their 
therapeutic performance as drugs are made available over pro-
longed periods of time.[70,73,122]
Hydrogel formulations are of particular interest for the con-
trolled and local delivery of anticancer drugs to improve their 
efficacy and reduce off-target side effects.[123,124] The most 
common cancer treatments involve local surgery or radiation 
therapy, as well as systemic approaches including chemotherapy, 
hormonal therapy, and antibody treatments.[125,126] Conventional 
chemotherapy based on cytotoxic small molecule drugs is con-
sidered a systemic treatment option for the elimination of can-
cerous cells and tissues, with the inherent limitation that these 
cytotoxic drugs often lack specificity toward cancerous cells 
versus healthy ones.[69,127] After systemic administration, drugs 
are distributed throughout the body and often only a small frac-
tion reaches the tumor site, whereas organs and nonmalignant 
tissues are frequently also negatively affected causing severe 
side effects.[69,127] Also, fluctuating drug levels represent a con-
cern as most cytotoxic drugs are released directly after admin-
istration causing sharp peaks and subsequent decline in the 
drug concentration, yielding inadequate therapy and severe side 
effects.[128] Consequently, there is a strong demand for targeted 
and controlled release technologies. Hydrogels, with tunable 
sustained release characteristics and injectable formulations, 
fuel legitimate hopes to improve drug efficacy and reduce the 
impact on healthy cells or tissues.
The recently reported concept of drug-integrated DNA Trojan 
Horses aims at overcoming the limitations and severe side 
effects of classical therapy by systemic injection, which is char-
acterized by strong off-target effects. With DNA Trojan Horses, 
an enhanced cellular uptake, higher accumulation of the drug 
in the target tissue, and a more efficient, localized release aim 
to achieve greater antitumor effects.[129] Cytotoxic nucleoside 
analogs, such as fluoroxidine, which are an important class of 
anticancer drugs, were directly integrated into DNA via solid-
phase synthesis. In a hierarchical self-assembly process, these 
drug-containing single-stranded DNAs can hybridize into 
Y-shaped motifs, which then assemble into nanogels with a 
precise drug loading ratio. These nanogels resemble spherical 
nucleic acid-like architectures constituting novel Trojan Horses 
for drug delivery and anticancer treatment.[129] In vitro experi-
ments showed that the fluoroxidine-containing nanogels pro-
vided rapid cellular uptake and effective drug release in the 
presence of DNases, resulting in an enhanced anticancer effect 
compared to the free drug as control.[129]
Another strategy for efficient cancer treatment employs 
light-triggered drug release by incorporating gold nanoparticles 
(AuNPs)[130] or gold nanorods (AuNRs)[124] into DNA hydrogels 
in combination with anticancer drugs such as Doxorubicin 
(Dox). Song et al. reported a hydrogel that was assembled by 
enzymatic ligation of X-shaped DNA building blocks composed 
of three sticky arms for cross-linking and one other arm.[124,130] 
Employing simple electrostatic interactions between the nega-
tively charged DNA and the positively charged gold substrates, 
AuNPs or AuNRs were loaded into the hydrogel, while Dox was 
simultaneously incorporated via intercalation into the DNA 
completing the drug delivery system (Figure 6a). Release of Dox 
was achieved through a photothermal effect after laser excitation 
of the AuNPs, which led to a heat shock and subsequent disas-
sembly of the whole construct. The cytotoxicity of this system 
was found to be boosted, illustrating the synergy between pho-
tothermal and chemo-therapeutic approaches in cancer treat-
ment. This led to a reduction in the necessary dosage of either 
the laser power or drug concentration providing opportunities 
to reduce side effects when applied in photothermal therapy.[130] 
Based on the closely assembled AuNPs with strongly coupled 
plasmon modes, these hydrogels could potentially also be 
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exploited as contrast agents in CT imaging or in radiosensiti-
zation competing against large AuNPs, with sizes of hundreds 
of nanometers that are typically used and exhibit increased tox-
icity, thus limiting their applications.[130]
Another attractive example was developed by Liao et al. 
who applied chemical, rather than physical triggers for drug 
release. They reported on microcapsules consisting of stim-
uli-responsive DNA hydrogels that released drugs in the 
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Figure 6. DNA-based hydrogels for drug delivery applications in anticancer therapy. a) DNA-based hydrogels as delivery vehicle for AuNPs and anti-
cancer drugs combining triggered drug release and photothermal therapy. The DNA hydrogel is degraded after excitation-induced heat generation, 
which disperses the AuNPs. Co-loading of the anticancer drug Dox facilitated light-controlled cargo release from the hydrogel, which is attractive for, 
i.e., computer tomography (CT), imaging contrast, or radiosensitization. Adapted with permission.[130] Copyright 2018, American Chemical Society. 
b) Triggered release of therapeutic molecules from stimuli-responsive DNA hydrogel microcapsules. Polymer chains were equipped with nucleic acid 
hairpin structures as well as single-strand tethers as hybridization and recognition units to achieve substrate-loaded stimuli-responsive hydrogel-
based microcapsules. Microcapsules were loaded with CaCO3 microparticles and the respective substrates, i.e., Dox, and functionalized with nucleic 
acid promoter units, which induce hybridization chain reaction (HCR) upon presence of the hairpin-modified chains. A hydrogel coating was formed, 
which, after the dissociation of the CaCO3 cores, yields substrate-loaded hydrogel microcapsules. Stimuli-responsiveness was implemented into the 
microcapsule by caged aptamer sequences recognizing, e.g., ATP. In the presence of ATP, the duplex-caged aptamer sequences are released and new 
substrate–aptamer complexes were formed thus releasing the Dox cargo molecules. Adapted with permission under the use of the Creative Commons 
Attribution 3.0 Unported license[131] Copyright 2017, the Authors, published by Royal Society of Chemistry. c) Triggered cancer drug release after targeted 
cancer cell recognition by using an aptamer-functionalized hydrogel system. Aptamer sequences are used as cross-links of DNA-grafted acrylamide 
polymers. The aptamers bind specifically to nucleolin receptors that are overexpressed in the membrane of many tumor cells. The enhanced affinity 
of the aptamer toward the nucleolin receptors effects changes of the aptamer conformation thus reducing the cross-linking density and leading to 
hydrogel dissolution, releasing the encapsulated drug Dox. Adapted with permission.[123] Copyright 2015, Elsevier.
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presence of specific ligands based on aptamer technology 
(Figure 6b).[131] In order to prepare the construct, first, drug-
loaded CaCO3 microcapsules were coated with a layer of 
poly(allylamine hydrochloride) and subsequently with poly-
acrylic acid. Finally, the construct was functionalized with 
nucleic acid promoter units. The promoter units induced a 
hybridization chain reaction in the presence of nucleic acid 
hairpin structures leading to a cross-linked DNA hydrogel 
that coats the particles. Stimuli-responsiveness was imple-
mented by incorporating ligand-specific aptamer sequences 
within several hairpin units. These microcapsules were able 
to release their cargo drug, Dox, in the presence of adenosine 
triphosphate (ATP) due to its interaction with the aptamer 
cross-links leading to the dissociation of the cross-linking 
nucleic acid duplex units and partial separation of the micro-
capsule shells. ATP is overexpressed in cancer cells making 
it an interesting trigger for site-selective release systems.[131] 
This strategy was further expanded to metal organic frame-
work nanoparticles (NMOFs) that are prepared as carriers 
for cargos like cancer drugs. Here, duplex DNA-capped drug-
loaded NMOFs have been developed to introduce stimuli-
responsiveness but are associated with shortcomings such 
as limited loading degrees and nonspecific drug leakage. To 
address these issues, DNA hydrogel-coated NMOFs were intro-
duced for controlled drug release.[132–134] The hydrogel-coated 
NMOFs revealed substantially higher drug loading compared 
to NMOFs locked by duplex DNA capping units.[133,134] In par-
ticular, the hydrogel-coated NMOFs do not show nonspecific 
drug leakage while exhibiting high cytotoxicity (40% within a 
time interval of 3 days after treatment) and selectivity toward 
MDA-MB-231 cancer cells.[132]
In addition, small triggering molecules, i.e., metabolites, or 
receptor proteins can bind and change the aptamer conforma-
tion inducing a switch from the DNA bound to an unbound 
state (Figure 6c).[123] This principle was employed for cancer 
cell recognition and targeted drug delivery of anticancer drugs 
like Dox. Nucleolin receptors are overexpressed on tumor cells 
and can be used to selectively target these cells for the delivery 
of anticancer ligands and nanoparticles.[135] Incorporation 
of anti-nucleolin binding aptamers as hydrogel cross-linkers 
induced dissolution of the hydrogel upon nucleolin binding, 
thus effecting drug release in biological environments.[123]
In addition to small molecules as drugs, other therapeuti-
cally active molecules may offer new avenues to treat diseases. 
In this context, protein therapeutics are of emerging interest 
for many indications as they combine biological activity, target 
selectivity, biodegradability, and biocompatibility.[136] However, 
their low plasma half-life, blood circulation, and membrane 
penetration often limit in vivo usage.[137] Therefore, the explora-
tion of novel delivery routes of protein therapeutics is of great 
interest and hydrogels represent an attractive option for gener-
ating local depots in vivo.
Osteoporosis represents a low bone mass disease and is char-
acterized by a deterioration of bone tissue that is connected with 
a high occurrence of bone fractures.[138] Incident rates of oste-
oporosis increase with age and currently available treatments 
are mainly systemic, which can lead to severe side effects.[138] 
It has been shown that Rho-inhibiting C3 toxins selectively 
target bone-resorbing osteoclast cells which cause brittle bones 
and enhanced risk of bone fractures.[139] Local delivery and 
release of the C3 protein toxin from a polypeptide-DNA hybrid 
hydrogel has been demonstrated as a promising method for the 
spatial and selective modulation of these bone-degrading osteo-
clast cells (Figure 7).[49] The hydrogel consisted of two compo-
nents: a) the polypeptide backbone derived from human serum 
albumin with grafted ssDNA sequences and b) dendritic DNA 
providing four sticky ends, two of which are complementary to 
the grafted ssDNA sequences for cross-linking and the other 
two hybridize the DNA-tagged C3 proteins.[47–49] The resulting 
DNA hybrid hydrogel revealed self-healing properties allowing 
local positioning by injection and controlled degradation by 
proteases and nucleases that boosted C3 release. It effectively 
reduced osteoclast migration and resorption activity in vitro 
without affecting the activity, viability, and proliferation of bone-
forming osteoblasts. Thereby, the hydrogel offers great poten-
tial for the local improvement of bone quality in osteoporotic 
bone and patient-specific prophylactic treatment of bones with 
a high fracture risk is conceivable.[49]
Another approach is based on aptamer-containing hydro-
gels that directly capture the bioactive molecules so that no 
chemical modifications of these molecules are required. The 
aptamer-containing hydrogels are particularly useful for the 
delivery and sustained drug release to specific cells or tissues. 
They are capable of storing and releasing bioactive molecules 
either sustainably,[70,71,123] periodically,[72] or through exte
rnal,[73,74,122,140] or mechanical triggers via direct cell–material 
interactions such as traction forces[141] by introducing aptamers 
that specifically bind the active ingredients. When incorporated 
into gels, aptamers specific to signaling proteins such as anti-
platelet derived growth factor-ββ (PDGF-ββ)[70–74] or vascular 
endothelial growth factor (VEGF)[73] increase the local con-
centration of these proteins thus retaining them longer in the 
gels compared to nonfunctionalized hydrogels. A triggered and 
sequential release of these proteins was achieved by applying 
the respective DNA replacement strands and subsequent 
hybridization and strand displacement as depicted schemati-
cally in Figure 8a.[72–74,122,140]
The principle of triggered and sequential protein release 
from DNA hydrogels was further expanded by spatially control-
ling the immobilization of proteins. Therefore, Zhang et al. pro-
posed a simplified approach using UV-light-induced thiol-ene 
click chemistry to produce an aptamer-patterned poly(ethylene 
glycol) (PEG) hydrogel by applying a photomask (Figure 8b,c). 
The photomask allows patterning within the hydrogel, where 
protein-binding aptamers are conjugated to the polymer net-
work in the areas exposed to UV light.[142,143] Protein loading 
occurs only within these regions and its release is triggered 
by hybridization of displacement strands to the aptamers 
(Figure 8b).[142] Using different protein-binding aptamers, 
multiple distinct proteins could be captured and released 
in a controlled fashion. It has been demonstrated that after 
incubation in a mixture of VEGF and PDGF-ββ proteins the 
respective binding and retention only occurred in those regions 
of the gel that were functionalized with the corresponding 
aptamer sequences (Figure 8c).[143] Using the displacement 
strand strategy, the proteins were released at predetermined 
time points. This combination of photo-patterning with two dif-
ferent aptamers gave both spatial and temporal control over the 
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release of two separate proteins even in complex environments 
such as human serum.[143] Good cytocompatibility was demon-
strated suggesting promising potential for in vivo usage. There-
fore, protein delivery is combined with patterning to realize 
spatially controlled immobilization and release of different 
proteins simultaneously or sequentially at distinct times and 
concentrations within 3D hydrogels.[143] The approach offers 
great potential to construct smart protein carriers for controlled 
release or biomimetic 3D micro-environments for cells.[142,143]
However, for certain applications it is not feasible to use 
DNA strands or other small molecules as the release trigger. 
Consequently, external triggers, such as light of specific wave-
lengths have been investigated to stimulate drug release. Light-
induced protein release from DNA hydrogels via sequential 
photoreaction and hybridization in a self-programming fashion 
is particularly attractive as light represents a well-controllable 
external stimulus.[78] An external light signal induces breakage 
of light-responsive groups within the DNA hydrogel releasing 
an oligonucleotide as an internal molecular signal.[78] These 
oligonucleotides diffuse to neighboring DNA–protein com-
plexes replacing the DNA, dissociating the DNA–protein com-
plex and thus releasing the protein cargo. Therefore, controlled 
PDGF-ββ protein release was demonstrated in a wound closure 
assay and the potential to regulate smooth muscle cell migra-
tion by the signal was highlighted.[78]
In addition to the discussed systems, the Almquist group 
has recently published a new approach that goes beyond the 
current usage of external triggers.[141] They eliminated the need 
for passive activation by, e.g., hydrolysis, spatially diffusive trig-
gers such as enzymes and pH changes, and even sophisticated 
exogenous triggers such as light by implementing cellular 
traction forces as innate stimulus. Briefly, aptamers were used 
as a substrate-independent, programmable platform, which is 
responsive to cellular traction forces, so-called TrAPs (traction 
force-activated payloads). Making use of the fact that aptamer 
binding constants rely on their ability to fold into a struc-
ture that binds to the relevant pocket on the targeted protein, 
Stejskalovà et al. developed a system where the activation of 
bioactive proteins was actively triggered by dynamic interac-
tions of cells with the biomaterial.[141] Here, the exertion of 
cellular traction forces triggered unfolding of the aptamers, 
which drastically reduced their binding affinity thus releasing 
the bound protein payloads, i.e., PDGF-ββ or VEGF-165. These 
aptamers were conjugated to a cell-adhesive peptide on the one 
end, and a chemical group on the other end enabling their con-
jugation to the polymer scaffold of interest. The functionality 
of such dynamic biomaterials was verified on planar structures 
and within clinically relevant 3D collagen sponges.[141] Even 
though the authors did not report on biomedical applications, 
based on the presented advanced proof-of-principle in vitro 
data, they suggest that this strategy forms the basis of a new 
method for integrating latent growth factor signaling within a 
wide range of biomaterial-based systems that are activated by 
their direct dynamic interactions with cells, opening new pos-
sibilities in designing dynamic biomaterial systems.[141]
The advantages of DNA-containing hydrogels for drug 
delivery applications rest on their programmability, reproduc-
ible drug-loading, biocompatibility, and biodegradability. In the 
context of cancer targeting, the possibilities offered by DNA 
hydrogels to release one or more drugs at precise locations and 
in predetermined doses may help overcome the resistance of 
certain hard-to-treat tumors, while minimizing detrimental 
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Figure 7. DNA-based hydrogels for application in bone regeneration. a) The DNA-protein hybrid hydrogel is assembled by cross-linking a serum 
albumin–derived polypeptide copolymer with grafted PEG and ssDNA side chains with dendritic DNA origami cross-linkers. Controlled release occurs 
via DNases. b) Design of injectable hydrogels that could inhibit osteoclast formation for local improvement of bone quality. Controlled release of C3 
hydrogels effectively reduced osteoclast resorption activity without affecting osteoblast, bone-forming cells, in vitro. Adapted under the terms of the 
Creative Commons Attribution-NonCommercial 4.0 International license.[49] Copyright 2017, The Authors.
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effects to healthy cells. However, the safe positioning of such 
local depots needs to be considered and they may not be suit-
able for addressing distant metastasis. As more stimuli for 
releasing compounds from DNA hydrogels are being devel-
oped, the potential uses also increase. Patterned hydrogel 
depots could be imagined as smart implants that can sense 
and react to biochemical processes of the individual patient, 
and release appropriate drugs in response to certain levels of 
analytes or metabolites. This would open great opportunities in 
advanced and personalized medicine.
3.3. Immunomodulatory DNA Hydrogels
The immune system represents the primary defense that pro-
tects the body against various infections and pathogens. Many 
vaccines have been developed to train the immune system to 
recognize pathogens.[144] Prophylactic vaccines are one of the 
most efficient therapies to prevent infective diseases, and they 
have been recognized for the treatment of certain cancers, 
namely, those of viral origin, such as hepatitis B virus and 
human papillomavirus (HPV).[144–147] However, many diseases 
are also associated with disorders of the immune system itself. 
On the one hand, an overactive immune system can be harmful 
to the person, e.g., in allergies, where foreign but harmless sub-
stances such as pollen, induce a severe immune reaction. In 
addition, healthy tissue can suddenly be mistaken as foreign 
and dangerous, resulting in a severe attack in autoimmune dis-
eases. Diabetes Type I, rheumatic arthritis, multiple sclerosis, 
and Lupus fall under the latter category.[144,145] In such states 
of hyperactive immune responses during autoimmune and 
inflammatory diseases,[145] as well as transplant rejection,[145] 
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Figure 8. a) Triggered cargo release from DNA-based hydrogels for therapeutic approaches. Release of multiple protein-drugs via strand displace-
ment. Aptamer-functionalized hydrogels are designed with adjustable release rates at predetermined time points using complementary sequences as 
biomolecular triggers. The color intensity of the balls indicates the protein amount, whereas light colors indicate fewer bound proteins. Adapted with 
permission.[73] Copyright 2012, American Chemical Society. b) Patterning and controlled release of therapeutic proteins as smart DNA-based hydro-
gels in biomedicine. 3D bioactive patterned hydrogels as biomimetic environments with spatio-temporally controlled release of bioactive proteins. 
The selective protein capturing and their spatial distribution were realized in an aptamer-patterned hydrogel. The system is based on the specific 
affinity between the aptamer and protein. Addition of complementary DNA strands (ssDNA) of the aptamer dissociates the protein cargo from the 
aptamer at desired time points and concentrations based on DNA hybridization. In this example, the spatial release of the protein thrombin in an 
aptamer-functionalized PEG hydrogel is shown within 1 h by adding the respective ssDNA. Adapted with permission.[142] Copyright 2017, Royal Society 
of Chemistry. c) Patterned hydrogel for spatio-temporally programmable capture and release of multiple proteins. To control the capture and release 
of multiple proteins in different hydrogel regions and at desired time periods was realized in aptamer-patterned hydrogels. By conjugating DNA of 
different aptamers via photoclick chemistry, spatio-temporally adjustable release rates can be realized for multiple proteins as both aptamer–protein 
interaction and aptamer–complementary ssDNA hybridization are highly specific. Here, two different aptamer–protein dissociations were triggered 
through complementary ssDNA releasing growth factors from aptamer-patterned hydrogel films providing a platform for aptamer functionalization 
and controlled protein release from hydrogel films. Adapted with permission.[143] Copyright 2018, American Chemical Society.
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the immune cell activation has to be reduced.[125,144] On the 
other hand, hypoactive conditions that appear in certain can-
cers or chronic infections often require the opposite approach 
of increasing the immune cell activation.[125,144]
In previous years, many new small molecules, proteins, or 
polymers have been developed as immunomodulators, some of 
which were also integrated into polymeric platforms.[144] Hereby, 
conventional treatment approaches aimed at therapeutic 
immune system modulation by administration of soluble com-
ponents, orally, nasally, or via local or systemic injection, and 
their dispersion throughout the body. However, only recently, 
polymeric scaffold-based immunomodulatory systems that can 
be implanted beneath the skin were reported and promise to 
treat different types of cancer, chronic infections, and autoim-
mune diseases.[144] In this context, the design of immunomodu-
lating hydrogels has become a rapidly growing field of research 
as they could be designed at multiple length scales (macro- to 
nanoscale) to target organs (e.g., lymph nodes, lymphoid 
residing cells, and their intracellular compartments), function 
as surrogate lymphoid-like tissues, and deliver multiple biomol-
ecules that could modulate the humoral and cellular immune 
response.[144] Here, DNA hydrogels are particularly interesting 
as they allow for the sustained release of bioactive molecules and 
guarantee intrinsic biodegradability over longer time frames.
Most research in the field of immunomodulatory DNA 
hydrogels centers on the utilization of unmethylated cytosine 
phosphate guanine (CpG) dinucleotide, the so-called CpG 
motif, in order to develop immunostimulatory soft materials 
for sustained release of signals.[148–152] The CpG motif is a well-
known pathogen-associated molecular pattern that resembles a 
danger signal, and it is recognized by the mammalian immune 
system via toll-like receptor 9 (TLR-9).[148,153–156] Subsequent 
release of proinflammatory cytokines stimulates the immune 
system.[155,156] While the effects of CpG motifs have yet to be 
fully elucidated, it is clear that CpG rapidly activates a variety 
of cell types spanning B cells, natural killer cells, and antigen-
presenting cells, including monocytes, macrophages, and den-
dritic cells.[155,156] The utilization of the CpG motif as a vaccine 
adjuvant seems promising and its implementation has been 
reported in a variety of DNA-based hydrogels, for applications 
spanning from immunotherapy against allergies to vaccination 
against cancer.[149,155–157] Besides, immobilization of CpG motifs 
within such gels can easily be obtained by hybridization. While 
the potent immune activating effect of CpG oligonucleotides 
was described the first time by Krieg et al. in 1995,[158] pointing 
out possible new applications as adjuvants, the first exam-
ples of DNA-based hydrogels containing the CpG motif[153,154] 
were reported by the Nishikawa group in 2010.[148] Building 
on this, newer systems with, sustained release of antigens for 
immunotherapy of, i.e., allergic rhinitis were subsequently 
described by the same group.[149–152] In a frequently reported 
strategy, six oligonucleotides and CpG motifs were assembled 
into dendritic DNA structures (Figure 9a,b).[149–152,159] The 
self-gelling and injectable CpG DNA hydrogel showed a high 
immunological potency and low toxicity as a vaccine adjuvant 
when loaded with ovalbumin (OVA), which is frequently used 
as a model antigen and serves as a proof-of-concept for many 
biomaterial-based vaccines[144] that is injected intradermally.[159] 
This was highlighted by the decrease in adverse reactions of the 
OVA/CpG DNA hydrogel compared to OVA injected with com-
plete Freund's adjuvant or alum, which are commonly used in 
experimental (Freund's adjuvant) or clinical (alum) vaccine for-
mulations.[159] Due to the self-gelling characteristics of the CpG 
DNA hydrogels, its administration into cavities or as a spray 
even allowed intranasal vaccination (Figure 9a).[149]
Rhinitis is caused by ragweed pollen and subcutaneous 
injection of CpG DNA conjugated antigen effectively prevented 
this disease in clinical studies.[160,161] The intranasal vaccination 
of Japanese cedar pollen (JCP) in mice also induced immuno-
therapeutic effects against allergic rhinitis.[149] CpG hydrogels 
loaded with Cryj1, a major JCP allergen, effectively induced 
allergen-specific immune responses in mice after intranasal 
administration, which was partially due to the sustained 
release of this antigen from the hydrogel.[149] The authors also 
proposed DNA hydrogels as a mucosal delivery system for 
shorter immunotherapy with a lower burden regarding their 
application by avoiding repeated subcutaneous injections.[149] 
To further broaden the applicability of the gel for oral delivery 
of CpG DNA antigens, the development of DNA hydrogel 
microspheres that were coated with chitosan was proposed to 
improve the stability and increase the intestinal transit time.[150] 
Further modifications focused on increasing the duration of 
sustained antigen and CpG DNA release from the hydrogels to 
increase their potency.[151,152] Two approaches for modifying the 
gels have been tested, namely, making use of electrostatic inter-
actions of the cationic polymer chitosan and DNA for stabili-
zation as the first approach and hydrophobic interactions from 
additional cholesterol groups as the second approach.[151,152] 
As a result, more efficient specific immune responses of OVA-
loaded CpG-DNA hydrogels were reported compared to the 
nonstabilized hydrogels.[151,152]
While the activation of the immune system for positive 
therapeutic effects has been a central but still elusive chal-
lenge in immunology and oncology for decades, recent clinical 
trials have significantly increased the chances of survival of 
patients with metastatic melanoma, for which conventional 
therapies have failed.[147] In this context, the emergence of 
targeted therapies and the ever advancing understanding of 
how antitumor immune responses are regulated, suggest 
that active immunotherapy is ideal to achieve efficient treat-
ment of cancer patients.[147] Hereby, it is pivotal to break the 
immunotolerance of the tumor and induce robust immunore-
sponses of the patient by applying a suitable vaccine and/or 
immunostimulant.[162]
Umeki et al. further advanced the introduced immunostim-
ulatory CpG DNA hydrogels for cancer immunotherapy, 
enhancing the antigen-specific antitumor immunity of the 
host by encapsulation of immune cells within the hydrogel, 
thereby, achieving co-delivery of the antigen and immune 
cells.[157] The hexapod-like DNA nanostructures featuring 
CpG motifs were also utilized in combination with gold nan-
oparticles to achieve tumor photothermal immunotherapy 
(Figure 9b). Here, Yata et al. created a composite-type DNA 
hydrogel, where gold nanorods functionalized with oligomers 
were intended to hybridize with immunostimulatory den-
dritic DNA during hydrogel formation.[163] These hydrogels, 
upon laser irradiation, release the hexapod-like DNA which 
efficiently stimulated immune cells.[163] Simultaneously, laser 
Adv. Funct. Mater. 2019, 1906253
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irradiation at 780 nm increased the local temperature, which 
consequently enhanced tumor-associated antigen-specific IgG 
levels in serum and interferon production from splenocytes, 
white blood cells from the spleen.[163–165] Such treatment sig-
nificantly retarded tumor growth and extended the survival of 
the tumor-bearing mice.[163]
In contrast to the presented hydrogels that were designed to 
present and deliver certain antigens, recently, Shao et al. devel-
oped an injectable DNA hydrogel vaccine (DSHV) that behaves 
like an endogenous lymph node (Figure 9c).[162] After intraperi-
toneal or subcutaneous injection, the DSHV served as an arti-
ficial lymph node, where the antigen-presenting cells (APCs) 
were recruited and activated in vitro and in vivo by high local 
CpG concentrations resulting in strong immune responses and 
antitumor effects. The recruiting of APCs into the gel and their 
subsequent activation effected by high antigen concentrations 
sets this hydrogel system apart from the previously presented 
vaccine-releasing systems.[162] These findings underline the 
emerging relevance of supramolecular DNA-based hydrogels 
as a general platform for tumor vaccination and cancer therapy 
in the future.[162] Complementing the field of immunostimula-
tory DNA hydrogels, recent attempts also envision the delivery 
of immunoinhibitory nucleic acids for the treatment of auto-
immune diseases, e.g., systemic lupus erythematosus, related 
to enhanced TLR9-mediated signaling.[156,166] The design of 
immunomodulatory materials is still in its infancy. With the 
advent of tumor immune therapy, the application of soft DNA 
hydrogels for the local, controlled release of immunogenic 
agents promises new therapeutic options for the treatment of 
certain cancers, infections, and other diseases.
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Figure 9. Immunomodulatory DNA hydrogels. a) Nasal vaccination by application of the controlled release of allergens using self-gelling immunostim-
ulatory DNA for effectively inducing immune responses. Immunostimulatory DNA hydrogels are obtained by mixing hexapod-like DNA nanostructures 
using six oligodeoxynucleotides each, including an unmethylated cytosine–phosphate–guanine sequence (CpG motif), with the allergen (Cryj1). The 
allergen features slow release from the stDNA hydrogel, which is retained in the nasal cavity after intranasal administration. Intranasal immunization 
of mice with the Cryj1/sDNA hydrogel results in high levels of Cryj1-specific IL-12. Adapted with permission.[149] Copyright 2015, Elsevier. b) Tumor 
photothermal immunotherapy using DNA-based composite hydrogels. Applying a composite-type immunostimulatory DNA hydrogel consisting of 
hexapod-like DNA nanostructures with CpG sequences and gold nanoparticles allows for the efficient stimulation of immune cells upon laser irradiation 
of the hydrogel due to the release of hexapod-like DNA nanostructures. The intratumoral injection was followed by laser irradiation which increased the 
local temperature. Significantly retarded tumor growth has been demonstrated. Adapted with permission.[163] Copyright 2017, Elsevier. c) Designable 
immune vaccine systems based on DNA hydrogels. An injectable DNA supramolecular hydrogel vaccine (DSHV) system was designed to efficiently 
recruit and activate APCs in vitro and in vivo, thereby, mimicking the function of a lymph node where the APCs are recruited and activated by the high 
local concentration of CpG. After injection, naive APCs were recruited and activated by the DSHV system, resulting in subsequent interaction of mature 
APCs with other immune cells yielding strong immune responses and antitumor effects. The DSHV can be fabricated through the self-assembly of DNA-
based Y-scaffold and linker, as well as antigen P1. CpG sequences are included in linker sequences, which are marked in bright green color. The antigen 
P1 contained a B-cell and a T-helper cell epitope is shown as a purple ball. Adapted with permission.[162] Copyright 2018, American Chemical Society.
www.afm-journal.dewww.advancedsciencenews.com
1906253 (17 of 25) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
3.4. DNA Hydrogels for Cell-Based Approaches  
and Tissue Engineering
The following section deals with DNA hydrogels that interact 
specifically with cells. These interactions are applied toward 
tissue engineering where extracellular matrix (ECM) mimics 
are generated that can precisely position bio-signals and even 
cells themselves, e.g., in tissue cultivation, as well as capture 
specific cells from circulation.
Tissue engineering has emerged as a key technology in 
regenerative medicine.[167–169] The introduction of cells and 
tissue constructs into the human body to replace or repair 
patient tissue is still a challenging endeavor as the “engineered” 
tissue should replicate the structure and function of the 
normal, healthy tissues as closely as possible.[170,171] Hydrogels 
have long since been applied as soft matrices due to their simi-
larities to soft tissue[171] and their innate structural and compo-
sitional similarities to the ECM provide an adequate framework 
for cellular proliferation and survival.[172,173] As a result, their 
usage as ECM mimics is a prevalent choice and different kinds 
of hydrogels with diverse chemical and physical properties 
have been proposed to enable cellular attachment and differen-
tiation in biodegradable matrices and facilitate solute nutrient 
transport.[171,174]
The thixotropic nature inherent to many DNA hydrogels is 
particularly useful toward tissue engineering applications, as 
new processing techniques could be applied such as bioprinting 
to mold the hydrogels, as bioink, into creating sophisticated 3D 
shapes[26] like 3D multilayers with complex structures and cell 
patterns.[26] Such soft materials could be preformed to fit var-
ious cavities when administered into the patient.[175] In addition, 
DNA-based hydrogels allow for the programmed dynamic and 
reversible display of various signals, positioned with nanoscale 
accuracy, to facilitate and control interactions with the ECM or 
cellular membrane.[9,176] The presentation of bioactive signals 
such as the RGD peptide motif that binds to integrin cell sur-
face receptors[9] is essential when designing ECM mimics for 
tissue engineering.[9,171] DNA-based hydrogels with short bioac-
tive peptide sequences such as RGD, IKVAV, or growth factor-
derived sequences were conjugated to DNA strands, which then 
hybridized with sticky ends of surface-exposed DNA.[9] Richards 
et al. developed a DNA-based system for surface modification 
of, e.g., acrylamide hydrogels yielding polyvalent display of 
affinity ligands for cell culturing (Figure 10a).[177] The synthesis 
of a polymeric DNA scaffold via hybridization chain reaction 
starting from single-stranded oligonucleotides was followed by 
hybridization of aptamers onto the hydrogel surfaces. As each 
DNA scaffold provided multiple sites for aptamer hybridization, 
surface functionalization with polyvalent aptamers was realized 
in a straightforward manner. Consequently, hydrogel surfaces 
functionalized with polyvalent ligands enhanced ligand display 
and 44% more cell binding was observed after 90 min com-
pared to surfaces directly conjugated with equal amounts of 
cell-specific aptamer.[177] This approach is especially interesting 
when limited surface areas or insufficient surface reaction sites 
are available.[177]
This study demonstrated a novel and highly efficient DNA-
based approach for the functionalization of surfaces employing 
polymerization of affinity ligands. However, the importance of 
multivalency for cell regulation and the control over dynamic 
signal display is another desirable material characteristic. 
Freeman et al. described a thin alginate layer that employed 
DNA to dynamically control and spatially arrange multiple bio-
active signals in order to mimic features of the ECM.[9] Thereby, 
bioactive peptide-DNA hybrid strands were immobilized on the 
surface through complementary DNA tethers, so-called surface 
strands (Figure 10b). A series of different DNA tethers varying 
in the degree of base-pair complementarity to the surface 
strands allows for programmed displacement of the functional 
DNA strands resulting in reversible switching of bioactivity. 
Thus, orthogonal and reversible display of multiple biomimetic 
signals as well as synergies between bioactive epitopes, which 
are spatially dependent, were promoted on a biomaterial using 
DNA as an adjustable spacer. As a result, cells were instructed 
to migrate or regroup as a direct response to a dynamic switch 
of exogenous signals for proliferation, such as a mimic of the 
fibroblast growth factor 2, or differentiation, like the peptide 
IKVAV.[9] Similarly, this technique could be beneficial for tissue 
engineering applications when used to modify hydrogel sur-
faces to direct cellular responses.
In addition to functional signal display, mechanical cues 
arising from ECMs also affect cellular properties and, there-
fore, the mechanical and rheological properties are of high 
significance in biomaterial design. Jiang et al. demonstrated 
that the tunable mechanical properties of polyacrylamide gels 
cross-linked with acrydite-oligonucleotides affect the neurite 
outgrowth of spinal cord neuronal cells in vitro.[44] By varying 
the length of the cross-linking strands or the stoichiometry of 
the linker strand to the bound oligonucleotides, they demon-
strated gel stiffnesses ranging from 100 Pa to 30 kPa. Such 
materials could be important for neuronal regeneration, e.g., 
in spinal cord injury as well as for neural tissue engineering 
including neuropathological conditions and neurodegenera-
tive diseases where the mechanical stiffness of tissue is being 
altered.[44,178,179]
However, despite the advances in the self-assembly of arti-
ficial hierarchical systems, approaches to create reversible and 
tunable structures that can be manipulated across different 
length scales remain challenging. Recently, Freeman et al. 
reported fibrous DNA hybrid hydrogels featuring reversible 
and dynamic self-assembly of superstructured networks mim-
icking the ECM (Figure 11a). Thereby, nanofibers were formed 
from peptide amphiphiles as well as peptides containing a 
covalently linked oligonucleotide terminal segment and were 
reversibly cross-linked by Watson–Crick base pairing between 
complementary oligonucleotides on separate fibers. Impor-
tantly, the resulting hydrogels exhibited hierarchical structures, 
which arose from the DNA-peptide amphiphiles’ dynamic 
reorganization. In contrast, disassembly occurred in response 
to chemical triggers such as ssDNA that mediated strand dis-
placement.[180] Two populations within the gel were observed, 
twisted fiber bundles as well as single fibers, and the switching 
between these two morphologies induced changes in cell 
activity, which was demonstrated for astrocytes (Figure  11A). 
A reactive phenotype was only observed when the astrocytes 
were cultured on the bundled fiber hydrogel resulting in the 
upregulation of cell marker proteins like glial fibrillary acid pro-
tein (GFAP) and an increase in reactive oxygen species (ROS). 
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As these important phenotype transformations in astrocytes 
that are linked to brain and spinal cord injury as well as neuro-
logical diseases were demonstrated to be modulated by architec-
tural cues, the authors suggest that future therapeutic strategies 
that “defibrillate” glial scars could be explored to reverse neural 
pathologies through astrocytic fate decisions.[180] In a follow-up 
work, Daly et al. further demonstrated the powerful concept 
of combining DNA with peptides.[181] Compared to the work 
of Freeman et al., where peptide amphiphiles were used,[180] 
here, the peptide–DNA hybrids were created with the very 
short dipeptide Fmoc-FF–OH[181] that is known to assemble 
efficiently into nanoscale fibers. The combination with oligonu-
cleotides of different lengths encoded the formation of revers-
ible supramolecular hierarchical fibrous assemblies that were 
tunable by temperature or pH changes, as well as the addition 
of soluble triggers such as DNase. Variation in the length of the 
DNA segment had an impact on the morphology, dimensions, 
and helicity of the obtained structures. The presented data sug-
gests that this technique could serve as a useful handle for the 
design of tunable, self-assembled architectures, and the authors 
envision its application in the areas of tissue engineering, drug 
delivery, and sensing.[181]
The precise positioning of a large number of specialized 
cells with different functions within a material is another 
central challenge in tissue engineering.[182] Additionally, in 
multicellular organisms, important cellular processes such 
as proliferation and differentiation are regulated by signaling 
from the ECM. A material that is able to recognize particular 
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Figure 10. a) Schematic illustration of DNA polymerization for enhanced display of aptamers and comparison of surfaces with equal aptamer 
amounts. At direct conjugation, individual aptamers were directly conjugated to the hydrogel while polyvalent display features polyvalent aptamers 
formed on the hydrogel surface. The kinetic analysis of cell binding on surfaces with the aptamer amount of 7 × and the comparison of cell binding 
on surfaces with equal amounts of aptamer. Adapted with permission.[177] Copyright 2014, American Chemical Society. b) Dynamic reversible 
switching of cell bioactivity via toehold-mediated strand displacement. The bioactive strand is removed by a fully complementary displacement 
strand, thus switching bioactivity OFF; this process regenerates the surface strand, allowing for a second addition of the RGDS-DNA to turn 
bioactivity back ON. This process can be repeated for multiple cycles. DNA surface strands with variable spacer regions tune the distance between 
the peptide signals RGDS and PHSRN. The right panel shows immunofluorescence images of neurospheres subjected to dynamic and orthogonal 
presentation of IKVAV and FGF-2 signals. Adapted under the terms of the Creative Commons Attribution 4.0 International license.[9] Copyright 
2017, The Authors.
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cell types and then allows for the controlled attachment of these 
cells in a programmable way would be highly desirable.[183] One 
approach in this direction focused on creating DNA-network-
based functional hydrogels as an artificial designer ECM on 
solid support.[183] The networks were generated by enzymatic 
elongation via PCR. In a first step, amine-functionalized 
primers and two different branched primers were used for PCR 
while the resulting product became conjugated to an activated 
glass surface. In a next step, primers that did not participate 
in the first PCR were elongated in a primer-extension reaction 
and the usage of branched primers leads to their incorpora-
tion into the surface bound network. Here, the utilization of 
functionalized primers, i.e., modified with the cyclic pep-
tide c(RGDfK), a bait molecule that is known to enhance cell 
adhesion of endothelial cells and fibroblasts gave rise to selec-
tive cell attachment through specific interactions with cell-sur-
face markers (Figure 11b). In this way, cell-repellent properties 
of the unfunctionalized DNA-based hydrogel were converted to 
adhesiveness toward specific target cells when functionalized 
with the respective bait peptide. The specific response of cells 
to the DNA-modified surfaces was demonstrated by applying 
different cell types like HeLa or mouse embryonic fibroblasts 
that are known to bind the RGD peptide motif and cells such 
as HEK293T cells that were reported to not interact.[184–186] 
Notably, the nature and concentration of displayed molecules 
can be controlled to address different types of cells while 
DNase treatment allows for mild and efficient detachment of 
the adhered and viable cells.[183]
Figure 11. DNA-based hydrogels in tissue engineering—mimicking tissue. a) Reversible and dynamic self-assembly of superstructured networks in 
DNA hybrid hydrogels mimicking the ECM. Applying DNA hybridization for further cross-linking of peptide amphiphile fibers yields hydrogels with 
hierarchical structures due to the DNA–peptide amphiphiles’ dynamic reorganization. Disassembly occurs in response to chemical triggers. Two 
populations can be observed within the gel, consisting of twisted fiber bundles as well as single fibers, and the switching between these two mor-
phologies can induce a switch in cell activity which is shown for astrocytes. A reactive phenotype (cells are false colored in blue) was observed when 
cultured on bundled fiber hydrogel (false colored in pink) resulting in the upregulation of GFAP and an increase in ROS. Adapted with permission.[180] 
Copyright 2018, American Association for the Advancement of Science. b) Designer ECM based on DNA–peptide networks with cell adhesion proper-
ties. The networks are constructed using covalently branched DNA as primers in PCR. As a covalent coating of surfaces, this DNA-based material 
shows cell-repellent properties in its unfunctionalized state. Adhesiveness toward specific target cells is introduced with the respective biological 
signal peptide upon application of functionalized primers. DNase treatment enables the release of the adhered and viable cells under mild conditions. 
Adapted with permission[183] Copyright 2016, Wiley-VCH. c) Multiplexed patterning of cells at single-cell resolution. In this approach, the cell membrane 
proteins are biotinylated and then addressed via streptavidin-conjugated oligonucleotides. Patterning of the respective DNA spots in a microarray and 
building an islet construct that includes, e.g., mouse α- and β-islet cell lines, represents the construction of model pancreatic tissues as an avenue 
toward engineering islets for type 1 diabetics. The transfer of patterned cells into thin, stackable hydrogel films extends the pattern into three dimen-
sions. Other than tissue engineering, cell-based assays or fundamental studies of cell–cell interactions are potential fields of application. Adapted with 
permission.[187] Copyright 2011, Wiley-VCH.
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The programmability of DNA hydrogels regarding their com-
position and structure is an essential feature, as engineered 
tissue constructs require correct spatial positioning of cell types 
to mimic the anatomical microarchitecture in native tissue.[187] 
Therefore, the ability to control the positioning of cells within a 
material down to individual cells would offer great opportuni-
ties for constructing complex tissues with distinct hierarchies. 
Oligonucleotide-modified hydrogel surfaces selectively recog-
nize distinct cell types with single cell-resolution due to com-
plementary binding. For example, Vermesh et al. reported mul-
tiplexed patterning of cells at single-cell resolution by labeling 
different cell types with a unique complementary oligonucleo-
tide strand in order to covert DNA arrays to defined cell arrays. 
The subsequent transfer of the patterned cells into thin, stack-
able hydrogel films allowed the assembly of 3D islet tissue-like 
constructs (Figure 11c).[187]
Apart from the applications in tissue engineering, con-
trolled DNA hydrogel–cell interactions have been exploited 
for the specific binding of circulating tumor cells (CTCs) 
(Figure 12a). CTCs are viable tumor-derived cells that circu-
late in peripheral blood and contain molecular information 
about the primary tumor. Capture of such CTCs for their 
direct detection could provide a simple and effective approach 
for early cancer diagnosis. Selective isolation would allow for 
predictive diagnosis and therapy avoiding complex invasive 
tumor biopsy.[188–192] However, despite great promise, many 
CTC detection techniques are costly, time-consuming, or need 
advanced instrumentation.[69,192] Another critical issue that 
still needs to be addressed is the specificity of the “cell catch” 
step, where the current technology can only achieve 50% 
purity in the identified CTCs. This is insufficient for reliable 
real-time monitoring of the cancer therapy response, early 
cancer detection, or the identification of CTC subpopulations 
such as metastatic precursor cells.[189] Taking advantage of the 
unique features of DNA nanomaterials, several approaches 
to construct DNA-based hydrogels that provide the ability to 
capture live cells with high specificity and in real-time, as 
well as releasing the captured, vital cells in response to an 
external trigger, have been reported. In contrast to many other 
systems, which involve harsh capturing conditions inducing 
nonphysiological stress and often damage the CTCs, aptamer-
functionalized nanostructures showed great promise for CTC 
capture.[75] Song et al. described a novel strategy for the highly 
specific cancer cell catch and gentle release. They designed 
an aptamer-triggered in situ gelation mechanism for liquid 
cloaking of CTCs for live-cell analysis. The aptamer-toehold 
conjugated DNA staple strands, aptamer-initiator diblocks, 
were chosen to bind specifically to epithelial cell adhesion 
molecule (EpCAM) on the cell surface that is overexpressed 
by most cancer cells and induces the clamped hybridization 
chain reaction (HCR). Notably, the cancer cell recognition 
elements are not limited to EpCAM but can be substituted 
by other proteins expressed on the cell surface. While many 
systems often also lack the ability for live cell release after 
capturing,[190] implementation of ATP-responsive regions in 
the clamped HCR yielded a stimuli-responsive DNA hydrogel 
which provides both simple and gentle CTC capturing and 
release, yet has great potential to gather reliable information 
on the primary tumor.[75]
Another system for cancer cell capturing on a hydrogel sur-
face was described by Zhang et al. who employed aptamer-func-
tionalized polyacrylamide hydrogels for triggered cell release via 
either complementary sequences or restriction endonucleases 
(Figure 12b). They described systems with low unspecific cell 
binding, but high specificity toward human leukemic lympho-
blast cancer cells on the hydrogel surface and excellent release 
efficiencies while maintaining cell viability.[77,193] Aptamer-
mediated cell recognition was also applied by Li et al. to develop 
a Drosera-bioinspired hydrogel for catching and killing cancer 
cells (Figure 12c). Mimicking the carnivorous plant Drosera 
which presents an adhesive surface to the environment and 
releases digestive enzymes on its leaves, a novel hydrogel 
capable of performing multiple functions, more precisely, a 
hydrogel with target-catching and drug-releasing functions was 
designed. To achieve this, a bifunctional hydrogel was gener-
ated by two hydrogel layers, both of which were functionalized 
with oligonucleotides. The top layer served as a surface for cap-
turing target cells through nucleic acid aptamers. The bottom 
layer hydrogel was chemically functionalized with a double-
stranded DNA, constituting a depot for sustained sequestration 
of small toxic drugs. In vitro studies with human leukemic 
lymphoblasts showed that the cancer cells can be caught effi-
ciently by the hydrogel followed by Dox release killing the 
cells. Repetitive display of the cell-catching aptamer on the 
cell surface combined with the sustained drug release further 
allows for killing cancer cells in a continuous fashion.[76] These 
examples highlight the exciting opportunities in creating cell-
compatible matrices from DNA hydrogels. The combination of 
adaptable mechanical properties, programmability, selectivity, 
and biocompatibility make DNA a promising material for var-
ious applications in tissue engineering.
4. Conclusion
The recent progress in preparing DNA-based hydrogels has 
made this material class accessible for exciting applications 
in the biomedical field. DNA building blocks provide unique 
characteristics that have prompted the development of highly 
sensitive biosensors, drug delivery systems, and cellular scaf-
folds for regenerative therapies. We anticipate that these 
examples only signify the beginning of a much larger trend 
that is to follow in the future. For example, the aptamer tech-
nology enables the design of DNA gels that can detect almost 
any type of analyte with high selectivity and sensitivity. New 
aptamers are easy to generate, leading to an ever-growing 
number of addressable targets. The same approach is also 
useful in selectively triggering the release of drugs, where 
DNA-based systems can provide a biocompatible and often 
more selective alternative to conventional chemical linker 
strategies. New concepts, such as rechargeable drug reser-
voirs, can now be conceived due to the programmable and 
reversible interaction of complimentary DNA strands. Fur-
thermore, the combination of novel DNA materials with new 
treatment approaches, as shown exemplarily for immuno-
therapy, holds great promise in the future for tackling dis-
eases with challenging diagnoses, insufficient or nonexistent 
treatment options. Finally, interesting mechanical properties 
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together with the option for versatile biofunctionalization of 
DNA hydrogels makes them attractive as cellular scaffolds, 
e.g., for tissue engineering.
Despite the tremendous progress in the development of 
DNA-based hydrogels, several challenges need to be addressed 
before a wide-spread usage will become feasible. First, the cost 
for the production of DNA needs to be further reduced to allow 
for cost-effective upscaling. We also believe that a biotechno-
logical approach might become suitable for producing DNA 
building blocks and even DNA nanostructures above a certain 
size,[4] but purification remains the critical issue. In contrast, 
synthetic methods are more suited for preparing short DNA 
fragments and especially when nonnatural functions need 
to be incorporated. Most likely, a combination of improved 
biotechnological production and automated DNA synthesis 
will provide the pathways to sufficient amounts of material as 
seen for peptide solid-phase synthesis and protein expression. 
Second, by developing new chemical handles as well as by 
incorporating un-natural nucleotides, the toolbox of DNA func-
tions could be expanded, which may lead to the discovery of 
completely new properties of DNA materials. For biomedical 
applications, the stability of the DNA constructs as well as their 
blood circulation and potential interactions with blood proteins 
need to be studied in greater details.
Overall, the unique programmability of DNA paves the 
way to smart therapeutic systems and we could imagine DNA 
Figure 12. a) DNA-based hydrogels for cell-based applications in anticancer therapy. Recognition, cloaking, and de-cloaking of circulating tumor cells 
(CTCs) via DNA hydrogel with aptamer-toehold. Capturing and analyzing rare live CTCs allow for predictive cancer diagnosis as they contain molecular 
information on the primary tumor. The aptamer-triggered clamped hybridization chain reaction (atcHCR) can be applied for in situ identification and 
subsequent cloaking/decloaking of CTCs by porous DNA hydrogels. A DNA staple strand with aptamer-toehold biblocks specifically recognizes epithe-
lial cell adhesion molecule on the CTC surface. Thereby, cells are captured directly with minimal cell damage. De-cloaking of CTCs using controlled and 
defined chemical stimuli can release living CTCs without damages for subsequent culture and live cell analysis. Adapted with permission.[75] Copyright 
2017, American Chemical Society. b) DNA-based hydrogels for application as cell-type-specific catch and release platforms. Programmable hydrogels 
for controlled cell catch and release using aptamer hybridization and complementary sequences. Cell–material interactions can be programmed 
by switching the binding states of cells on a hydrogel surface using hybridized aptamers for cell-type-specific catch and triggering complementary 
sequences yielding dissociation of the aptamers from the hydrogel and simultaneous cell release. The programmable hydrogel is regenerable and can 
be applied to a new round of cell catch and release when needed. Adapted with permission.[77] Copyright 2012, American Chemical Society. c) DNA-
based hydrogel for cell attraction, catch and killing of diseased cells (e.g., cancer cells) inspired by Drosera. The combination of a two-layered hydrogel 
is presented to afford a material with multiple functions that can be performed synergistically or sequentially. The hydrogel consists of two layers, the 
top layer is functionalized with oligonucleotide aptamers allowing for catching of target cells with high efficiency and specificity while the bottom layer 
hydrogel is functionalized with double-stranded DNA which can sequester intercalated drug for sustained drug release, killing the cells bound to the 
top layer in close proximity. Subsequent to cell release, the bifunctional hydrogel can be regenerated for continuous cell catching and killing. Adapted 
under the terms of the Creative Commons Attribution 4.0 International License.[76] Copyright 2015, The Authors.
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hydrogels as tissue-like components that locally detect changes 
in their environment and release distinct quantities of different 
therapeutics on demand. In this way, exciting future opportuni-
ties for personal medicine could be envisioned.
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